Actinium Pharmaceuticals to present ATNM-400 data at EANM 2026
The company plans to present first-in-human clinical data in prostate cancer and preclinical lung cancer results today.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Actinium Pharmaceuticals to present ATNM-400 cancer-model data at EANM 2026
The company announced oral and poster presentations highlighting broad antitumor activity across lung, colorectal and ovarian cancer models.
Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM — 400 in Prostate Cancer at EANM
Actinium Pharmaceuticals will present early Phase 1 results for prostate cancer therapy ATNM-400 on October 19, 2026, at EANM in Vienna. Initial clinical data support advancing the non-PSMA-targeted radiotherapy for metastatic castration-resistant prostate cancer. ATNM-400 targets patients with low or absent PSMA expre